Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer - NICE TAG TA416

1.1 Osimertinib is recommended as an option for use within the Cancer Drugs Fund for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has progressed only:

• after first-line treatment with an EGFR tyrosine kinase inhibitor and

• if the conditions in the managed access agreement for osimertinib are followed.

1.2 This guidance is not intended to affect the position of patients whose treatment with osimertinib was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta416